Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-37735
Titel: Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells
VerfasserIn: Nini, Alessandro
Hoffmann, Michèle Janine
Lampignano, Rita
Große Siemer, Robert
van Dalum, Guus
Szarvas, Tibor
Cotarelo, Cristina Lopez
Schulz, Wolfgang Arthur
Niederacher, Dieter
Neubauer, Hans
Stoecklein, Nikolas Hendrik
Niegisch, Günter
Sprache: Englisch
Titel: Clinical Cytometry
Bandnummer: 98
Heft: 4
Seiten: 355-367
Verlag/Plattform: Wiley
Erscheinungsjahr: 2020
Freie Schlagwörter: circulating tumor cells
EpCAM
HER2
urothelial carcinoma
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Background Detection of circulating tumor cells (CTC) by techniques based on epithelial cell adhesion molecule (EpCAM) is suboptimal in urothelial carcinoma (UC). As HER2 is thought to be broadly expressed in UC, we explored its utility for CTC detection. Methods HER2 and EpCAM expression was analyzed in 18 UC cell lines (UCCs) by qRT-PCR, western blot and fluorescence-activated cell scanning (FACS) and compared to the strongly HER2-expressing breast cancer cell line SKBR3 and other controls. HER2 expression in UC patient tissues was measured by qRT PCR and correlated with data on survival and risk for metastasis. UCCs with high EpCAM and variable HER2 expression were used for spike-in experiments in the CellSearch system. Twenty-one blood samples from 13 metastatic UC patients were analyzed for HER2-positive CTCs with CellSearch. Results HER2 mRNA and protein were broadly expressed in UCC, with some heterogeneity, but at least 10-fold lower than in the HER-2+ SKBR3 cells. Variations were unrelated to cellular phenotype or clinicopathological characteristics. EpCAM expression was essentially restricted to UCCs with epitheloid phenotypes. Heterogeneity of EpCAM and HER2 expression was observed also in spike-in experiments. The 7 of 21 blood samples from 6 of 13 patients were enumerated as CTC positive via EpCAM, but only one sample stained weakly positive (1+) for HER2. Conclusions Detection rate of CTCs by EpCAM in UC is poor, even in metastatic patients. Because of its widespread expression, particularly in patients with high risk of metastasis, detection of HER2 could improve identification of UC CTCs, which is why combined detection using antibodies for EpCAM and HER2 may be beneficial.
DOI der Erstveröffentlichung: 10.1002/cyto.b.21877
URL der Erstveröffentlichung: https://onlinelibrary.wiley.com/doi/10.1002/cyto.b.21877
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-377352
hdl:20.500.11880/34125
http://dx.doi.org/10.22028/D291-37735
ISSN: 1552-4957
1552-4949
Datum des Eintrags: 26-Okt-2022
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Urologie und Kinderurologie
Professur: M - Prof. Dr. Michael Stöckle
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons